Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 168,559,200
  • Shares Outstanding, K 1,764,833
  • Annual Sales, $ 33,266 M
  • Annual Income, $ 7,882 M
  • 60-Month Beta 0.83
  • Price/Sales 4.92
  • Price/Cash Flow 8.97
  • Price/Book 11.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 2.79
  • Number of Estimates 4
  • High Estimate 2.87
  • Low Estimate 2.76
  • Prior Year 2.33
  • Growth Rate Est. (year over year) +19.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
91.78 +3.58%
on 08/06/20
101.28 -6.13%
on 07/17/20
-2.79 (-2.85%)
since 07/13/20
3-Month
87.43 +8.74%
on 05/14/20
101.28 -6.13%
on 07/17/20
+6.20 (+6.98%)
since 05/13/20
52-Week
62.55 +51.99%
on 03/23/20
101.28 -6.13%
on 07/17/20
+30.06 (+46.24%)
since 08/13/19

Most Recent Stories

More News
Easy Investing Secrets to an Early Retirement - August 13, 2020

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices,...

BMY : 63.49 (-0.24%)
AMGN : 240.20 (-0.63%)
ABBV : 94.91 (-0.63%)
AbbVie Outperforms Large-Cap Pharma Industry Year to Date

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.

RHHBY : 43.4300 (+0.14%)
NVS : 85.21 (+0.33%)
ABBV : 94.91 (-0.63%)
GMAB : 37.79 (+3.88%)
US Biosimilars Market Size to Reach $22,996 Million by 2027; Recent Scientific Discoveries Have Indicated Signs of a Promising Future, says Fortune Business Insights(TM)

The US Biosimilars Market size is projected to reach USD 22,966 million by the end of 2027. The presence of several large scale companies that are engaged in the research and development of efficient biosimilars...

ABBV : 94.91 (-0.63%)
AMGN : 240.20 (-0.63%)
CHRS : 19.33 (+2.28%)
LLY : 150.53 (-1.32%)
PFE : 38.01 (-0.83%)
TEVA : 11.60 (-0.34%)
3 Healthcare Stocks with Over 3% Dividend Yield

The healthcare sector has come to the forefront as the cornonavirus pandemic has influenced our daily activities. Some stocks are worth your time, while others aren't. If you're looking for dividend income,...

ABBV : 94.91 (-0.63%)
PFE : 38.01 (-0.83%)
PDCO : 26.78 (-1.03%)
GILD : 68.12 (-1.05%)
BNTX : 70.95 (+2.66%)
New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients

, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the publication of results from the Phase 3 VIALE-A clinical study in patients with AML in the .The study, which evaluated newly-diagnosed AML patients...

ABBV : 94.91 (-0.63%)
Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

PFE : 38.01 (-0.83%)
NVS : 85.21 (+0.33%)
MRK : 83.11 (+0.52%)
LLY : 150.53 (-1.32%)
JNJ : 148.09 (-1.05%)
AZN : 55.78 (-1.69%)
ABBV : 94.91 (-0.63%)
Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts

Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.

EBS : 134.09 (+3.49%)
HZNP : 72.05 (-0.83%)
ABBV : 94.91 (-0.63%)
RETA : 103.94 (+0.61%)
Signs That Your Trading Will Ruin Your Retirement - August 11, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

ABBV : 94.91 (-0.63%)
BMY : 63.49 (-0.24%)
AMGN : 240.20 (-0.63%)
Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y

Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.

EBS : 134.09 (+3.49%)
ABBV : 94.91 (-0.63%)
EDIT : 35.22 (+1.35%)
CTLT : 88.61 (+0.92%)
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - August 10, 2020

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income...

ABBV : 94.91 (-0.63%)
CVS : 64.79 (-0.31%)
CMRE : 5.27 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ABBV with:

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

2nd Resistance Point 97.06
1st Resistance Point 96.28
Last Price 94.91
1st Support Level 94.03
2nd Support Level 92.56

See More

52-Week High 101.28
Last Price 94.91
Fibonacci 61.8% 86.49
Fibonacci 50% 81.92
Fibonacci 38.2% 77.34
52-Week Low 62.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar